Patient Controlled Injectors Market Report 2024

The patient-controlled injectors market size has grown rapidly in recent years. It will grow from $4.01 billion in 2023 to $4.51 billion in 2024 at a compound annual growth rate (CAGR) of 12.5%. Historic period growth was driven by the expansion of home healthcare services, healthcare infrastructure development, rising diabetes prevalence, increasing infectious diseases, and growing adoption of personalized medicine.

The patient-controlled injectors market size is expected to see rapid growth in the next few years. It will grow to $7.32 billion in 2028 at a compound annual growth rate (CAGR) of 12.8%. Forecast period growth is anticipated due to an aging population, higher incidence of chronic respiratory diseases, increased prevalence of chronic illnesses, rising cancer rates, and growing prevalence of autoimmune disorders. Key trends in this period include technological advancements, integration of artificial intelligence, telemedicine, remote monitoring, advances in portable and wearable devices, and emphasis on minimally invasive procedures.

The rising prevalence of chronic diseases is poised to drive the growth of the patient-controlled injectors market in the coming years. Chronic illnesses, lasting three months or more and often worsening over time, are increasing due to factors such as an aging population, the obesity epidemic, socioeconomic conditions, and environmental factors. Patient-controlled injectors enable individuals to self-administer medications accurately, conveniently, and according to their treatment schedules. For example, the National Center for Biotechnology Information (NCBI) projected in January 2023 that the number of individuals aged 50 and older with one or more chronic conditions will rise by 99.5% by 2050, from 71.52 million in 2020 to 142.66 million. Therefore, the growing prevalence of chronic diseases is expected to propel the patient-controlled injectors market forward.

Leading companies in this market are innovating by developing advanced products such as ready-to-use syringes to better meet customer needs. Ready-to-use syringes come prefilled and sterilized with a precise dose of medication, eliminating the need for manual preparation and reducing risks of contamination and dosing errors. For instance, in October 2022, Ypsomed AG introduced a new autoinjector platform tailored for liquid pharmaceuticals ranging from 1.5 to 5.5 ml. This device features ergonomic design for ease of use, ensuring patient comfort during injections, along with advanced safety mechanisms to prevent accidental needle sticks. It provides visual and audible feedback to confirm successful medication delivery and is versatile for various therapeutic applications due to its compatibility with different viscosities.

In April 2023, LTS Lohmann Therapie-Systeme AG expanded its drug delivery portfolio by acquiring the sorrel wearable injection device business from Eitan Medical. This acquisition enhances LTS's capabilities in advanced wearable injection technologies, further solidifying its presence in the patient-controlled injectors market. Eitan Medical Ltd. is an Israel-based company that develops innovative drug delivery devices, including patient-controlled injectors.

Major companies operating in the patient controlled injectors market are Medtronic plc, Becton Dickinson and Company, West Pharmaceutical Services, SCHOTT AG, Gerresheimer AG, Phillips-Medisize, Vetter Pharma-Fertigung GmbH & Co. KG, Stevanato Group, Ypsomed AG, Nemera, B. Braun Melsungen AG, Elcam Medical, Owen Mumford, Bespak, Unilife Corporation, Crossject, SHL Group, AptarGroup Inc., Credence MedSystems, Weibel CDS AG, Sorrel Medical.

North America was the largest region in the patient controlled injectors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the patient controlled injectors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the patient controlled injectors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Patient-controlled injectors are medical devices designed to empower patients to self-administer medication with precise control over dosage and timing. They are user-friendly, facilitating independent management of treatment, typically in home settings.

The primary types of patient-controlled injectors include electronic wearable injectors, mechanical wearable injectors, and infusion pumps. Electronic versions enable automated and precise medication delivery, often equipped with connectivity features for tracking and monitoring usage. This enhances convenience and provides data-driven insights for patients. These devices find applications in treatments such as cancer, autoimmune disorders, and blood disorders, distributed through hospital pharmacies, retail pharmacies, and mail-order channels.

The patient-controlled injectors market research report is one of a series of new reports that provides patient-controlled injectors market statistics, including patient-controlled injectors industry global market size, regional shares, competitors with a patient-controlled injectors market share, detailed patient-controlled injectors market segments, market trends, and opportunities, and any further data you may need to thrive in the patient-controlled injectors industry. This patient-controlled injectors research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The patient-controlled injectors market consists of sales of prefilled syringes, auto-injectors, on-body injectors, and needle-free injectors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.